Eurasian Medtech System Battles To Be In Place This Year

The Eurasian Economic Union's system for regulating medtech products is dropping into place, but too slowly as some see it, and still with many questions remaining over the content. However, it remains a fixture for the future, and device companies serving the region need to be prepared.

The Eurasian Economic Union’s common market for medical technology products retains a headline target of starting to take device submissions before the end of the year. To many, including Alexey Stepanov, regulatory manager for Russia and the CIS with Abbott Molecular Inc., this is an unlikely eventuality.

Addressing the "emerging markets regulatory affairs" stream of Informa Life Sciences Medtech Summit 2016 in Brussels (June 13-16), Stepanov provided a brief journey-so-far for the three already-integrated members of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By 

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

FDA Draft Guidance Introduces Electric Submission For Q-Sub Process

 

The US FDA says its updated draft guidance represents one of several steps the agency is taking to develop electronic submission templates for the medical device industry. The document introduces stakeholders to currently available resources for supporting their pre-subs to the agency.